Key takeaways from world's largest cancer conference in Chicago
Doctors, scientists and researchers shared new findings on ways to tackle cancer at the 2025 American Society of Clinical Oncology annual meeting, the world's largest cancer conference.
The event in Chicago, attended by about 44,000 health professionals, featured more than 200 sessions on this year's theme, Driving Knowledge to Action: Building a Better Future. Here is a roundup of the key studies.
An immunotherapy drug could help some cancer patients live years longer without the disease getting worse or coming back, a trial found.
Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years, compared to 30 months with standard care. It also cut the risk of the disease returning in another part of the body.
A second study showed people with a deadly form of skin cancer could live longer with an innovative one-time immunotherapy.
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, the trial found.
Car T-cell therapy is a new form of immunotherapy where a patient's own T-cells – a type of white blood cell – are tweaked in a lab to target and kill cancer cells. The designer cells are then infused back into their bloodstream to fight the disease.
One trial found cancer patients treated by Car T-cell therapy can live 40% longer.
The therapy has already proved successful in treating blood cancers. Now results from the world's first randomised controlled trial of Car T-cell therapy in solid tumours suggest it could be transformative in the fight against these cancers too.
Solid tumours represent about 90% of all cancers, including breast, lung and pancreatic cancer.
In the trial hailed as a 'milestone' by experts, patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer treated with Car T-cell therapy lived on average about 40% longer than patients who received standard care.
A second Car T-cell therapy shrank tumours in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported in Chicago.
'Seeing recurrent [glioblastoma] tumours shrink like this is extraordinary, because the immunotherapy drugs that we've tried in the past have been unable to do that,' said the study's lead author, Dr Stephen Bagley, of the University of Pennsylvania.
In a world first, doctors announced at the conference that thousands of cancer patients in England would benefit from a DNA blood test that saves lives by fast-tracking them on to personalised treatments.
The liquid biopsy looks for circulating tumour DNA (ctDNA) to find specific genetic variations of cancer. The NHS will offer it to patients with lung and breast cancer – two of the most common forms of the disease.
Rapid results mean patients can immediately be offered drugs and treatments specifically tailored to the genetic profile of their disease, significantly increasing their survival chances and paving the way for a new era of precision medicine.
Exercise slashes the risk of death in cancer patients by more than a third, a landmark trial found. Physical activity could also prevent the disease coming back and stop new tumours developing, as well as lifting mood, reducing fatigue and boosting strength.
The world's first randomised clinical trial to specifically evaluate if a structured exercise regime after treatment could reduce the risk of recurrence or new cancers in patients took place over more than a decade.
Hailed as gamechanging by experts, the results show it could. The trial found patients had a 37% lower risk of death and a 28% lower risk of their cancer coming back or new cancers developing, compared with patients who received only health advice.
'When we saw the results, we were just astounded,' said the study's lead author, Dr Christopher Booth, of Queen's University in Kingston, Canada.
Margaret Tubridy was one of 889 patients with colon cancer recruited to the trial from six countries – the UK, US, Australia, France, Canada and Israel. Five years after her diagnosis, she told the Guardian she was now free of cancer and healthy, with no signs of the disease coming back.
Amid a series of breakthroughs aimed at tackling the most common cancer in women, doctors were told a new drug can stop some breast cancer tumours before they grow.
A trial showed that camizestrant stops cancer cells from using hormones to grow, which helps patients stay well longer and delays the need for chemotherapy. It was the first global study to show that using blood tests to find early signs of cancer resistance to treatment helps patients.
The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases. Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with standard therapies.
'This is going to be very impactful for our patients,' said Dr Hope Rugo, the head of breast medical oncology at City of Hope hospital in Duarte, California.
A second trial found that a new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further chemotherapy and helps patients live longer.
Artificial intelligence could help end a 'postcode lottery' for a life-extending treatment for prostate cancer, researchers said.
Abiraterone is a hormone therapy described as a 'gamechanger' that works by blocking the production of testosterone, which fuels prostate cancer growth.
It has already helped hundreds of thousands with advanced prostate cancer to live longer. But some countries, including England, have stopped short of offering the 'spectacular' drug more widely to men whose disease has not spread.
A team from the US, UK and Switzerland have built an AI test that shows which men would most likely benefit from abiraterone. The breakthrough will enable healthcare systems to roll out the drug to more men, and spare others unnecessary treatment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News
an hour ago
- Sky News
Blood test for Alzheimer's disease is highly accurate, researchers say
Researchers say a new blood test for Alzheimer's disease has been shown to be highly accurate in detecting people with early symptoms. Scientists looked for two proteins - amyloid beta 42/40 and p-tau217 - and found the test was 95% accurate in identifying patients with existing cognitive impairment linked to the condition. The US study involved 509 patients in an outpatient memory clinic in Florida and was published in the medical journal Alzheimer's and Dementia. The test, which has already been approved by the US regulator, was also 82% accurate for specificity, which means it could rule out people without dementia. Dr Gregg Day, who led the study, said the test was as good as existing, but more invasive, tests. He said the next step was to extend the test to a wider range of patients, including those with early Alzheimer's who do not have any cognitive symptoms. Scientists say the two proteins, which they have identified in blood plasma, are associated with the buildup of amyloid plaques. Amyloid protein can be found in our brains, but in Alzheimer's disease, amyloid sticks together and forms abnormal deposits, which are thought to be toxic to brain cells. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results "suggest this test is very accurate". "Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before," he added. In the UK, the Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. 1:09 Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: "We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal." She said the studies like the Blood Biomarker Challenge are a "crucial part of making diagnosis easier and faster, which will bring us closer to a cure". "The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK," she added.
Daily Mail
2 hours ago
- Daily Mail
ANDREW NEIL: Like a clown running into a minefield, Musk threw caution to the wind, but he's right - Trump's 'big beautiful bill' IS a 'disgusting abomination'
Well, that didn't take long. When I boarded a flight for New York on Thursday, Donald Trump and Elon Musk were still sticking to the script: though the dizzy days of their bromance might be over, the separation was amicable. The most powerful man in the world and the richest even staged a chummy farewell in the Oval Office last week to underline the point. Yet by the time I'd landed at JFK just over seven hours later, Washington's version of Krakatoa had erupted.
The Guardian
3 hours ago
- The Guardian
Switch on those glutes! Suddenly it's all about the bass, and for good reason
I'm staring at the screen, trying to write a joke. It involves a muscle called the gluteus maximus, Roman centurions and possibly a reference to Biggus somebody from Monty Python's Life of Brian. I've been sitting here for over an hour, so long that when I finally stand up I have to hobble and wobble a few steps before I can get my stride back. It's because my glutei maximi are a bit of a joke. I have spent so much of my life literally sitting on this Roman-sounding muscle, staring at screens, trying to think up killer first lines to stories that by middle-age this undernourished workhorse is vocalising its disappointment at my life choices. Everyone seems to be talking about glutes right now and it's not just some fad brought on by Kim Kardashian's internet-breaking bum. Fitness instructors tell us to 'switch on those glutes', or admonish us for having 'lazy' glutes or 'dead butt syndrome'; suddenly, it's all about the bass. And it's for good reason. The gluteal muscles are vital for getting us up and about, yet humanity's increasingly sedentary lifestyle and work are leading to neglect of our glute health, with potentially serious consequences for our overall health. Let's meet the triumvirate of the tush muscles: gluteus maximus, gluteus medius and gluteus minimus. Maximus is, as the name suggests, the big one that makes up what might colloquially be known as the butt cheek and which attaches at the back of the pelvis and at the side of the thigh bone. 'Glute max is largely responsible for extending your hips, so pushing your leg behind you,' says associate professor Angie Fearon, a physiotherapist at the University of Canberra. 'If you're standing up and you pushed your leg backwards, that would be that muscle … it pushes you forwards when you're walking, or running or hopping or skipping.' Gluteus medius and minimus take the leg out to the side and manage the rotational movement. These three muscles are vital in keeping the pelvis stable during walking, lifting the leg up and powering us forward. They are also a link from the core muscles in the stomach and the lower back down to the muscles of the legs. Weak gluteal muscles can lead to what Dr Charlotte Ganderton describes as a teapot-style gait, where people tilt their upper body from side to side over their hip as they walk. 'They're actually throwing their whole torso over their hip to be able to clear their foot through, and that obviously has significant consequences on the rest of your body and the joints that are further up from the hip, so the spine,' says Ganderton, a physiotherapist at RMIT and Alphington Sports Medicine in Melbourne. The real problem with neglected gluteal muscles is what they can lead to. 'If you don't have good functioning gluteal muscles, the actual hip joint is the one who takes on those forces,' Ganderton says. 'People that have hip pathology – so hip arthritis, lateral hip pain, which people call gluteal tendinopathy – we know that these individuals have poor hip strength, and they often have very poor hip control when we assess them in the clinic.' The two most common hip conditions that affect particularly older people are hip osteoarthritis and gluteal tendinopathy, which is sometimes also called greater trochanteric pain syndrome or bursitis. 'What we see in people with those conditions is they're often weaker in that area than an asymptomatic control group,' Fearon says. With gluteal tendinopathy, pain develops because weaker gluteal muscles leads people to overuse other muscles, which then cause irritation and inflammation of the tendons and muscles in the outer hip region. And for many, our sedentary lifestyle is to blame – it is very much a case of 'use it or lose it'. Even two weeks of sitting on our backsides with little to no activity can be enough to start deconditioning and diminishing of our muscles. Further on from that, 'the muscle no longer stays as muscle tissue, for the most part – it actually fills with fat and what we call fatty infiltrate', Ganderton says. And once that happens, it can be very challenging to reverse and rebuild the muscle. However the exercises to strengthen the gluteal muscles are actually pretty basic. The simplest one is called a 'gluteal bridge' and just involves lying on your back, planting the soles of your feet on the floor or bed and lifting your pelvis up off that surface. Or while you're lying down, roll on to your side and lift the upper leg upwards to about the width of your shoulders. Ganderton's own research in postmenopausal women with gluteal tendinopathy found that a simple standing exercise could also help. 'Standing on one leg where you've got both knees straight and you just lift up the opposite leg about a centimetre off the floor, so just weight shifting across uses a lot of muscle activity in the leg that's standing on the ground,' she says. For the more active and stable among us, Fearon also recommends squats and walking lunges, carrying weights if you're up to it. Even these simple exercises can make a big difference, Fearon says. 'Say you had 100 people with gluteal tendinopathy, in a large percentage of them, if you got them to do some specific strengthening work for the hip abductors, and you gave them some suitable education, they'd probably all improve or a large percentage of them would.' But at the most basic level, we just need to move more. 'There's really good evidence that shows that if you get up and move every 20 to 30 minutes – get up, do a few squats, go and get a glass of water, go to the photocopier, just get up and move – it actually sets off a whole lot of enzymes in your muscles, which is good,' she says. 'Your brain gets a break and overall you do better.'
